Artivion (AORT) Projected to Announce Quarterly Earnings on Thursday

Artivion (NYSE:AORT) is anticipated to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.0612) per share and revenue of $120.97 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. The firm had revenue of $125.76 million during the quarter, compared to analysts’ expectations of $119.99 million. On average, analysts expect Artivion to post $0.45 EPS for the current fiscal year and $0.77 EPS for the next fiscal year.

Artivion Trading Up 4.5%

Shares of AORT stock opened at $23.59 on Tuesday. The firm has a fifty day moving average price of $23.78 and a 200-day moving average price of $29.36. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.47 and a quick ratio of 2.51. Artivion has a 1 year low of $19.16 and a 1 year high of $48.25. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -336.89 and a beta of 1.23.

Insider Buying and Selling at Artivion

In related news, CEO James Mackin sold 70,000 shares of Artivion stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total value of $2,026,500.00. Following the sale, the chief executive officer owned 877,275 shares of the company’s stock, valued at approximately $25,397,111.25. This trade represents a 7.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Andrew Green sold 11,480 shares of Artivion stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $24.97, for a total transaction of $286,655.60. Following the sale, the senior vice president directly owned 40,160 shares in the company, valued at approximately $1,002,795.20. This trade represents a 22.23% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 90,460 shares of company stock valued at $2,557,366. Corporate insiders own 6.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on AORT. Jefferies Financial Group began coverage on shares of Artivion in a research report on Tuesday, October 20th. They set a “buy” rating and a $31.00 price objective for the company. Citigroup restated a “market outperform” rating on shares of Artivion in a research report on Tuesday, July 21st. Needham & Company LLC reiterated a “buy” rating and issued a $44.00 target price on shares of Artivion in a report on Monday, July 20th. Weiss Ratings downgraded Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Canaccord Genuity Group increased their target price on shares of Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $42.86.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company’s products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care.